文献速递乳腺癌

HR+/HER2+早期乳腺癌中降阶梯新辅助T-DM1联合或不联合内分泌治疗对比曲妥珠单抗联合内分泌治疗的5年生存:WSG-ADAPT-TP试验

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
PubMed 文献 · J Clin Oncol · 2023-02-21

WSG-ADAPT-TP II期试验随机分配375例中心复核的HR+/HER2+早期乳腺癌(临床I-III期)患者,接受12周T-DM1联合或不联合内分泌治疗或曲妥珠单抗联合内分泌治疗。三组5年侵袭性疾病无生存率和总生存率相似,达到病理完全缓解者5年iDFS优于未达到者,达到pCR后省略辅助化疗者与接受辅助化疗者5年iDFS相似。

要点

  • T-DM1、T-DM1+内分泌治疗与曲妥珠单抗+内分泌治疗三组5年iDFS和总生存率相似。
  • 达到pCR者5年iDFS为92.7%,未达到pCR者为82.7%,风险比为0.40(95%CI 0.18-0.85)。
  • 117例达到pCR的患者中41例未接受辅助化疗,接受与未接受辅助化疗者5年iDFS相似。

核心结论

  • 12周无化疗降阶梯新辅助治疗后达到pCR与HR+/HER2+早期乳腺癌极好生存相关,且无需进一步辅助化疗。
  • 尽管T-DM1±内分泌治疗较曲妥珠单抗+内分泌治疗的pCR率更高,但由于未达到pCR后强制标准化疗,所有试验组结局相似。
  • WSG-ADAPT-TP表明此类降阶梯试验在HER2+早期乳腺癌中可行且对患者安全。
  • 基于生物标志物或分子亚型的患者选择可能提高无化疗全身HER2靶向方法的疗效。

研究设计与样本

  • WSG-ADAPT-TP(ClinicalTrials.gov标识符NCT01779206)II期试验,375例中心复核的HR+/HER2+早期乳腺癌(临床I-III期)患者随机分配。
  • 患者按1:1:1随机接受12周T-DM1联合或不联合内分泌治疗,或曲妥珠单抗联合内分泌治疗,每3周一次。
  • 达到病理完全缓解(pCR)的患者允许省略辅助化疗(ACT)。
  • 本研究报告次要生存终点和生物标志物分析,分析至少接受一剂研究治疗的患者。
  • 生存分析采用Kaplan-Meier法、双侧log-rank统计和按淋巴结及绝经状态分层的Cox回归模型,P值<0.05认为有统计学意义。

主要发现

  • T-DM1、T-DM1+内分泌治疗和曲妥珠单抗+内分泌治疗组5年侵袭性疾病无生存(iDFS)率分别为88.9%、85.3%和84.6%(Plog-rank=0.608)。
  • 三组5年总生存率分别为97.2%、96.4%和96.3%(Plog-rank=0.534)。
  • 达到pCR者与未达到pCR者5年iDFS率分别为92.7%和82.7%,风险比为0.40(95%CI 0.18-0.85)。
  • 117例达到pCR的患者中41例未接受辅助化疗,接受与未接受辅助化疗者5年iDFS率分别为93.0%(95%CI 84.0-97.0)和92.1%(95%CI 77.5-97.4),Plog-rank=0.848。
  • 转化研究显示,PIK3CA野生型、高免疫标志物表达和luminal-A型(按PAM50)肿瘤在降阶梯抗HER2治疗下预后极好。

关键数值与推荐

  • 达到pCR者与未达到pCR者5年iDFS率分别为92.7%和82.7%,风险比为0.40(95%CI 0.18-0.85)。
  • 117例达到pCR的患者中41例未接受辅助化疗,接受与未接受辅助化疗者5年iDFS率分别为93.0%(95%CI 84.0-97.0)和92.1%(95%CI 77.5-97.4),Plog-rank=0.848。
  • T-DM1、T-DM1+内分泌治疗和曲妥珠单抗+内分泌治疗组5年iDFS率分别为88.9%、85.3%和84.6%(Plog-rank=0.608)。
  • 三组5年总生存率分别为97.2%、96.4%和96.3%(Plog-rank=0.534)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neoadjuvant chemotherapy is standard of care in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), irrespective of the hormone receptor status. Trastuzumab-emtansine (T-DM1), antibody-drug conjugate, is highly effective in HER2+ EBC; however, no survival data are available for de-escalated antibody-drug conjugate-based neoadjuvant therapy without conventional chemotherapy. PATIENTS AND METHODS: In the WSG-ADAPT-TP (ClinicalTrials.gov identifier: NCT01779206) phase II trial, 375 centrally reviewed patients with hormone receptor-positive (HR+)/HER2+ EBC (clinical stage I-III) were randomly assigned to 12 weeks of T-DM1 with or without endocrine therapy (ET) or trastuzumab + ET once every 3 weeks (ratio 1:1:1). Adjuvant chemotherapy (ACT) omission was allowed in patients with pathologic complete response (pCR). In this study, we report the secondary survival end points and biomarker analysis. Patients who received at least one dose of study treatment were analyzed. Survival was analyzed using the Kaplan-Meier method, two-sided log-rank statistics, and Cox regression models stratified for nodal and menopausal status. P values < .05 were considered statistically significant. RESULTS: T-DM1, T-DM1 + ET, and trastuzumab + ET induced similar 5-year invasive disease-free survival (iDFS; 88.9%, 85.3%, 84.6%; Plog-rank = .608) and overall survival rates (97.2%, 96.4%, 96.3%; Plog-rank = .534). Patients with pCR versus non-pCR had improved 5-year iDFS rates (92.7% v 82.7%; hazard ratio, 0.40 [95% CI, 0.18 to 0.85]). Among the 117 patients with pCR, 41 did not receive ACT; 5-year iDFS rates were similar in those with (93.0% [95% CI, 84.0 to 97.0]) and without ACT (92.1% [95% CI, 77.5 to 97.4]; Plog-rank = .848). Translational research revealed that tumors with PIK3CA wild type, high immune marker expression, and luminal-A tumors (by PAM50) had an excellent prognosis with de-escalated anti-HER2 therapy. CONCLUSION: The WSG-ADAPT-TP trial demonstrated that pCR after 12 weeks of chemotherapy-free de-escalated neoadjuvant therapy was associated with excellent survival in HR+/HER2+ EBC without further ACT. Despite higher pCR rates for T-DM1 ± ET versus trastuzumab + ET, all trial arms had similar outcomes because of mandatory standard chemotherapy after non-pCR. WSG-ADAPT-TP demonstrated that such de-escalation trials in HER2+ EBC are feasible and safe for patients. Patient selection on the basis of biomarkers or molecular subtypes may increase the efficacy of systemic chemotherapy-free HER2-targeted approaches.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Harbeck N, Nitz UA, Christgen M, et al. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol. 2023. PMID: 36809046. doi:10.1200/JCO.22.01816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。